BioCryst Pharmaceuticals
BCRX
133 hedge funds and large institutions have $826M invested in BioCryst Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 25 reducing their positions, and 11 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 25
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
53% more call options, than puts
Call options by funds: $8.87M | Put options by funds: $5.79M
8% more funds holding
Funds holding: 123 → 133 (+10)
1% more capital invested
Capital invested by funds: $817M → $826M (+$8.86M)
0.25% less ownership
Funds ownership: 92.34% → 92.09% (-0.25%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.7M |
| 2 |
Millennium Management
New York
|
+$6.41M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.11M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.08M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$14.3M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.45M |
| 4 |
Jennison Associates
New York
|
-$5.98M |
| 5 |
DM
Deerfield Management
New York
|
-$3.2M |
BCRX Hedge Fund Activity: Q1 2019 in Review
133 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2019, worth a combined $826M — up 1.1% from $817M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new BCRX positions and 11 closed out — a net gain of 10 holders — while 52 added to existing stakes and 25 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $12.7M. The largest seller was RA Capital Management, cutting an estimated $17.1M.
- 133 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2019, up from 123 in Q4 2018.
- Funds reported $826M of BioCryst Pharmaceuticals stock for Q1 2019, up 1.1% quarter-over-quarter.
- 21 funds opened new BioCryst Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of +10 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2019 was Citadel Advisors, an estimated $12.7M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2019 was RA Capital Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q1 2019.